A recent study published in Analytical Chemistry reveals the groundbreaking potential of Raman spectroscopy in cancer diagnostics, particularly for leukemia.
This collaborative effort, led by our CHARM partner Renzo Vanna of the Italian National Research Centre (CNR), involved researchers from both the biomedical and photonics fields. They used high-resolution Raman spectroscopy to study over 300 patient-derived leukaemia cells and successfully distinguished subtypes based on unique molecular signatures. Each subtype of leukaemia has unique molecular characteristics, and accurate classification is crucial for effective treatment. Traditional methods typically rely on a combination of clinical tests, including blood counts, bone marrow examinations and genetic studies. However, these methods can sometimes be limited in their ability to distinguish between closely related subtypes or to detect subtle molecular differences that could inform treatment decisions.
This is where Raman imaging comes in. By analysing the way light scatters off molecules inside a cell, scientists can create detailed ‘fingerprints’ of its molecular make-up. In this study, the more than 1.3 million spectra generated from 19 bone marrow samples provided a wealth of information about the cell’s biochemical environment and correctly identified key biomarkers, such as myeloperoxidase and haemoglobin, for distinguishing between different types of leukaemia cells.
The same data can be used to produce high-quality pseudo-stained images, a significant leap beyond traditional, subjective diagnostic methods. This advance could pave the way for more accurate and efficient leukaemia diagnosis, ultimately leading to more targeted treatments.
Overall, this work demonstrates how cutting-edge imaging based on Raman spectroscopy can significantly improve cancer diagnosis and patient care, and offers a glimpse into the future of precision oncology.
More details in the open access article: https://pubs.acs.org/doi/10.1021/acs.analchem.4c00787
–